Zorifertinib - AstraZeneca
Alternative Names: AZD-3759; Zorifer; Zorifertinib hydrochloride - AstraZenecaLatest Information Update: 25 Nov 2024
At a glance
- Originator AstraZeneca
- Developer Alpha Biopharma; AstraZeneca
- Class Amines; Antineoplastics; Piperazines; Quinazolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Cancer metastases; Non-small cell lung cancer
Most Recent Events
- 22 Nov 2024 Phase-II clinical trials in Cancer metastases (Combination therapy, Second-line therapy or greater) (PO), before November 2024 (Alpha Biopharma pipeline, November 2024)
- 22 Nov 2024 Phase-II clinical trials in Cancer metastases (Second-line therapy or greater) (PO), before November 2024 (Alpha Biopharma pipeline, November 2024)
- 22 Nov 2024 Phase-II clinical trials in Non-small cell lung cancer (Second-line therapy or greater) (PO), before November 2024 (Alpha Biopharma pipeline, November 2024)